Carcinoembryonic antigen : An invaluable marker for advanced breast cancer

Journal of Postgraduate Medicine

Volumn 42, Issue 3, 1996, Pages 68-71

  Pathak, K A ^a   Khanna, R ^a   Khanna, H D ^a   Khanna, S ^a   Gupta, S ^a   Khanna, N N ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Metastasis; Prognosis; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; BREAST DISEASE; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; DISEASE COURSE; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; BREAST DISEASES; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0030177465     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Robertson JF, Ellis IO, Bell J, et al. Carcinoembryonic antigen immunocytochemistry in primary breast cancer. Cancer 1989; 64(8):1638-45.
2. Horowitz JD, Au FC, Tang CK, Stein B, Campana TJ. Tissue carclno-embronic antigen level in benign and malignant diseases of the breast. J Surg Oncol 1989; 40(1): 58-60.
3. Wanebo NH, Rao B, Pinsky C, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 229: 446-50.
4. Repetto L, Onetto M,Gardin G, et al. Serum CEA, CA 15-3 and MCA in breast cancer patients: A clinical evaluation. Cancer Detect Prev 1993; 17(3): 414-5.
5. Zamcheck N. The expanding field of colorectal cancer markers: CEA, the prototype. Cancer Bull 1981; 33: 141-51.
6. Chu TM, Nemoto T. Evaluation of carcinoembryonic antigen in human mammary carcinoma. J Natl Cancer Inst. 1973; 51: 1119-22.
7. Steward AM, Nixon D, Zamcheck N, Aisenberg A. Carcinoembryonic antigen in breast cancer patients: Serum levels and disease process. Cancer 1974; 33: 1246-52.
8. Lokich JJ, Zamcheck N, Lowenstein M. Sequential CEA levels in the therapy of metastasis breast cancer. Ann Int Med 1978; 89: 902-6.
9. Tormey DC, Walkes TP, Snyder JJ, et al. Biological markers in breast Cancer. III. Clinical correlation with carcinoembryonic antigen. Cancer 1977; 39: 2397.
10. Chatal JF, Chupin F, Ricolleau G, et al. Use of serial carcinoembryonic antigen assays in detecting relapses in breast cancer involving high risk of metastasis. Eur J Cancer 1981; 17(2):233-8.
11. Molina R, Zanon G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36(1):41-8.
12. Haagensen DE, Barry WF, McCook TA, et al. The value of serial plasma levels of carcinoembryonic antigen and gross cyst disease fluid production in patients with breast carcinoma and the osseous metastases. Ann Surg 1980; 191: 599-603.
13. Mughal AW, Hortobagyi GN, Fritsche HA, et al. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA 1983; 249: 1881-6.
14. Borthwick NM, Wilson DW, Bell PA. Carcinoembryonic Antigen (CEA) in patients with breast cancer. Eur J Cancer 1977; 13: 171-76.
15. Heller R, Fisher R, Nash A, Knapp J. Lack of relationship between parity and level of carcinoembryonic antigen in women with breast cancer. Anticancer Res 1990; 10(6): 1755-57.
16. Bhatavdekar JM, Balar DB, Shah NG, et al. Prognosis in breast carcinoma utilizing plasma carcinoembryonic antigen and histologic characteristics of primary tumors. Tumor Biol 1987; 8(5): 233-40.
17. Rasmuson T, Bjork GR, Damber L et al. Tumor markers in mammary carcinoma. An evaluation of carcinoembryonic antigen, placental alkaline phosphatase, pseudouridine and CA 50. Acta Oncol 1987; 26(4): 261-7.
18. Esteban JM, Felder B, Ahn C, et al. Prognostic relevance of carcinoembryonic antigen and estrogen status in breast cancer patients. Cancer 1994; 74(5): 1575-83.
19. Omar YT, Behbehani AE, Al Naqueeb N, et al. Carcinoembryonic antigen and breast carcinoma antigen (CA 15-3) in preoperative staging and postoperative monitoring of patients with carcinoma of the breast. Int J Biol Markers 1988; 3(3): 165-71.
20. Al-Jarallah MA, Behbehani AE, el-Nass SA, et al. Serum CA 15-3 and CEA patterns in postsurgical follow-up and in monitoring clinical course of metastasis cancer in patients with breast carcinoma. Eur J Surg Oncol 1993; 19(1): 74-;9.
21. Ballesta AM, Molina R, Filella X, Jo J, Gimenez N. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumor Biol 1995;16(1): 32-41.
22. Coveney EC, Geraghty JG, Sherry F, et al. The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers 1995; 10(1): 35-41.